All In MedTech

Device Trial Radar · NCT05230992

Optimization of the Sensitivity of Histological Diagnosis of Pulmonary Nodules

Optimization of the Sensitivity of Histological Diagnosis of Pulmonary Nodules Using Cryoprobes Versus Standard Biopsy Forceps During Distal Sampling Guided by Mini Radial Ultrasound Probes

Last checked: Nov 19, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Nov 5, 2022

Primary completion

Nov 30, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
ElsanAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 9, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In pulmonary oncology, the diagnosis of medium-sized pulmonary nodules (10 to 20 mm), too distal to be reached by standard bronchial fibroscopy but remaining proximal, is difficult. There are 2 techniques: transthoracic puncture-biopsy under CT scan, usually performed by radiologists, and distal sampling guided by radial ultrasound mini-probe. The limitations of the last technique could be overcome by the use of cryoprobes for sampling, as they would take more tissue by freezing.

Conditions

  • Nodule

Interventions

  • Cryoprobes FirstDevice

    In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.

  • Cryoprobes SecondDevice

    In this second experimental group, the same medical devices are used but in the other order.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Validity of samples by cryoprobesTime frame: Within 24 hours after intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pneumologie Elsan Santé Atlantique

    Saint-Herblain, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.